Patents Assigned to ONCOBIX CO., LTD.
  • NOVEL DEUTERIUM-SUBSTITUTED PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
    Publication number: 20230114177
    Abstract: A novel deuterium-substituted pyrimidine derivative compound of Formula 1, or a pharmaceutically acceptable salt thereof is disclosed. A composition containing the compound and uses thereof in treating cancer are also disclosed.
    Type: Application
    Filed: December 15, 2020
    Publication date: April 13, 2023
    Applicant: ONCOBIX CO., LTD.
    Inventors: Sung-Eun KIM, Sunho LEE, Rengasamy RAJESH, Yong Hyub LEE, Yun Jeong KONG
  • NOVEL HETEROCYCLIC-SUBSTITUTED PYRIMIDINE DERIVATIVE EXHIBITING CANCER CELL GROWTH INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
    Publication number: 20220204492
    Abstract: The present invention provides a novel compound represented by Chemical Formula 1 or a salt thereof and a pharmaceutical composition for treating lung cancer containing same. A pyrimidine derivative compound represented by Chemical Formula 1 effectively inhibits the growth of cancer cells with an ALK mutation and an EGFR mutation, thereby being effectively usable in the treatment of lung cancer.
    Type: Application
    Filed: October 8, 2020
    Publication date: June 30, 2022
    Applicant: ONCOBIX CO., LTD.
    Inventors: Sung-Eun KIM, Sunho LEE, Rengasamy RAJESH, Yong Hyub LEE, Sung Tak HONG
  • Pyrimidine derivative having effect of inhibiting cancer cell growth and pharmaceutical composition containing same
    Patent number: 11248003
    Abstract: A novel pyrimidine derivative compound and a salt thereof are disclosed. The pyrimidine derivative compound effectively inhibits the growth of C797S mutant EGFR-expressed and MET-amplified cancer cells, which are the main resistance mechanisms of third generation EGFR anticancer agents, and thus may be effectively used in the treatment of lung cancer.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: February 15, 2022
    Assignee: ONCOBIX CO., LTD.
    Inventors: Sung-Eun Kim, Sunho Lee, Rengasamy Rajesh, Dae Ho Kang, Hyung Chui Ryu, Jae-Sun Kim, Sangryul Lee, Kyong Cheol Kim, Jin Kyung Rho, Jae Cheol Lee
  • NOVEL PYRIMIDINE DERIVATIVE HAVING EFFECT OF INHIBITING CANCER CELL GROWTH AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
    Publication number: 20210147439
    Abstract: A novel pyrimidine derivative compound and a salt thereof are disclosed. The pyrimidine derivative compound effectively inhibits the growth of C797S mutant EGFR-expressed and MET-amplified cancer cells, which are the main resistance mechanisms of third generation EGFR anticancer agents, and thus may be effectively used in the treatment of lung cancer.
    Type: Application
    Filed: December 6, 2018
    Publication date: May 20, 2021
    Applicant: ONCOBIX CO., LTD.
    Inventors: Sung-Eun KIM, Sunho LEE, Rengasamy RAJESH, Dae Ho KANG, Hyung Chul RYU, Jae-Sun KIM, Sangryul LEE, Kyong Cheol KIM, Jin Kyung RHO, Jae Cheol LEE